CVS Health (NYSE:CVS) has been given a $95.00 target price by analysts at Mizuho in a report issued on Wednesday. The brokerage currently has a “buy” rating on the pharmacy operator’s stock. Mizuho’s price objective points to a potential upside of 17.40% from the company’s previous close.
A number of other equities analysts have also weighed in on the company. Robert W. Baird reissued a “hold” rating and issued a $77.00 target price on shares of CVS Health in a research report on Friday, October 27th. Needham & Company LLC raised CVS Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $69.02 to $79.00 in a research report on Friday, November 10th. Deutsche Bank reissued a “hold” rating on shares of CVS Health in a research report on Tuesday, December 5th. Raymond James Financial reissued a “buy” rating on shares of CVS Health in a research report on Monday, December 4th. Finally, Royal Bank of Canada set a $95.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Monday, December 4th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $87.49.
Shares of CVS Health (NYSE:CVS) traded up $0.48 during trading on Wednesday, reaching $80.92. 7,310,000 shares of the company were exchanged, compared to its average volume of 8,530,000. The company has a market cap of $81,970.00, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.27 and a beta of 0.90. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.00. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.61% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pathstone Family Office LLC increased its position in shares of CVS Health by 341.0% during the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock valued at $2,353,000 after purchasing an additional 982 shares during the last quarter. Wealthcare Advisory Partners LLC increased its holdings in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares in the last quarter. Fieldpoint Private Securities LLC increased its holdings in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares in the last quarter. Arcadia Investment Management Corp MI increased its holdings in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares in the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in CVS Health in the 2nd quarter worth approximately $119,000. 81.70% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by American Market News and is the sole property of of American Market News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/24/mizuho-analysts-give-cvs-health-cvs-a-95-00-price-target.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
